SCHEDULE 13D: Guardian Pharmacy Services Founders Disclose Significant Class A Ownership and Future Share Conversions

A group of founders and key investors in Guardian Pharmacy Services, Inc. have filed a Schedule 13D, disclosing their collective beneficial ownership of 46.5% of Class A common stock and outlining the automatic conversion schedule for their Class B shares.

Summary

• A group of nine Reporting Persons, including Bindley Capital Partners I, LLC, William E. Bindley, Thomas J. Salentine, Jr., Pharmacy Investors, LLC, John Ackerman, Cardinal Equity Fund, L.P., Fred P. Burke, David K. Morris, and G. Kendall Forbes, have jointly filed a Schedule 13D regarding their ownership in Guardian Pharmacy Services, Inc.
• As of January 28, 2025, the Reporting Persons collectively beneficially own 10,570,152 shares of Class A common stock, representing approximately 46.5% of the total Class A common stock outstanding.
• This percentage is calculated based on 22,723,558 shares of Class A common stock outstanding, which includes 9,200,000 shares outstanding as of November 1, 2024, and 13,523,558 shares of Class A common stock expected to be issued on March 28, 2025, from Class B conversions.
• The Reporting Persons collectively acquired 42,137,748 shares of Class B common stock during the Issuer's Corporate Reorganization and Initial Public Offering (IPO) on September 27, 2024.
• These Class B shares will automatically convert into Class A common stock on a one-for-one basis in four substantially equal tranches on March 28, 2025, September 27, 2025, March 28, 2026, and September 27, 2026.
• The Reporting Persons, referred to as 'Guardian Founders,' entered into a Stockholders' Agreement on September 25, 2024, which includes provisions for director nomination rights and voting agreements.
• The agreement stipulates that Bindley Capital will designate two board nominees, Cardinal and Pharmacy Investors will collectively designate one, and Messrs. Burke and Morris will each be nominees, with the remaining three independent directors selected by the board.
• Guardian Founders have agreed to vote their shares in favor of these nominees and, for other votes, in the manner determined by a majority of their collective shares.
• The Stockholders' Agreement also imposes restrictions on 'Significant Stockholders' (those owning 10% or more) from acquiring additional equity or transferring shares to competitors without board consent until the seventh anniversary of the agreement.
• The Reporting Persons state their acquisition of shares is for investment purposes and they will continue to review their investment, potentially acquiring or disposing of shares in the future.

Sentiment

Score: 6

Explanation: The document provides clear and structured information regarding significant beneficial ownership and a defined corporate governance framework post-IPO, which is generally positive for transparency and stability. The inherent nature of a 13D filing is disclosure, not performance, so a neutral-to-slightly positive sentiment is appropriate for the clarity provided.

Positives

• The filing provides clear transparency regarding the significant beneficial ownership structure of Guardian Pharmacy Services, Inc. by its founders and key investors.
• The defined conversion schedule for Class B to Class A shares offers clarity on future share liquidity and the evolution of the company's capital structure.
• The Stockholders' Agreement establishes a clear corporate governance framework, including director nomination rights and voting agreements, which can contribute to stable leadership.
• The stated intention of the Reporting Persons to hold shares for investment purposes suggests a long-term commitment to the company's success.

Negatives

• The concentration of voting power among the 'Guardian Founders' through the Stockholders' Agreement could limit the influence of other Class A shareholders on certain corporate decisions.
• Restrictions on 'Significant Stockholders' from acquiring additional equity or transferring shares to competitors without board consent could potentially limit future strategic flexibility or market activity for these large holders.

Risks

• Concentrated voting power among the 'Guardian Founders' may lead to decisions that primarily benefit the controlling group, potentially at the expense of minority shareholders.
• The staggered conversion of Class B shares into Class A shares over multiple tranches could introduce periodic fluctuations in the Class A share float and liquidity.
• Restrictions on share transfers to competitors or other large holders could limit potential strategic partnerships or M&A activities involving significant blocks of shares.

Future Outlook

The Reporting Persons intend to continuously review their investment in Guardian Pharmacy Services, Inc. They may acquire additional securities or dispose of existing holdings through various means, subject to the Stockholders' Agreement. Future decisions will consider factors such as the Issuer's business and prospects, other business opportunities, changes in law and regulations, general economic conditions, and market price of the securities.

Management Comments

• William E. Bindley and Thomas J. Salentine, Jr. share voting and investment power over Bindley Capital's Class B common stock by virtue of their positions as members and officers of Bindley Capital Partners, LLC, the manager of Bindley Capital.
• John Ackerman has voting and investment power over Pharmacy Investors' Class B common stock by virtue of his position as Manager of Pharmacy Investors, LLC.
• Messrs. Burke, Morris, and Forbes are principally engaged in the business of management of Guardian Pharmacy Services, Inc.

Industry Context

This Schedule 13D filing primarily details changes in the ownership structure and corporate governance of Guardian Pharmacy Services, Inc. following its recent IPO and corporate reorganization. It does not provide direct insights into broader industry trends or competitive dynamics within the pharmacy services sector, but rather clarifies the control and influence of its founding investors.

Corporate Governance

Related Party Transactions

• The Stockholders' Agreement, dated September 25, 2024, is a key related party transaction between Guardian Pharmacy Services, Inc. and its 'Guardian Founders' (the Reporting Persons), outlining governance, voting, and share transfer rights and restrictions.

Stakeholder Impact

• **Shareholders**: The conversion of Class B to Class A shares will increase the float of Class A common stock over time, potentially impacting liquidity. The defined governance structure provides clarity on control and voting power.
• **Management**: The Stockholders' Agreement outlines the composition of the board of directors, ensuring representation from key founding members and investors, which can influence strategic direction.
• **Creditors**: The filing primarily concerns equity ownership and governance, with no direct impact on creditors mentioned.

Next Steps

• Automatic conversion of Class B common stock into Class A common stock will occur in four equal tranches on March 28, 2025, September 27, 2025, March 28, 2026, and September 27, 2026.
• The Reporting Persons will continue to review their investment in the Issuer on an ongoing basis.
• The Reporting Persons may acquire additional securities or dispose of existing holdings in the future, as permitted by the Stockholders' Agreement.

Key Dates

Keywords

Guardian Pharmacy Services, SEC filing, Schedule 13D, beneficial ownership, Class A common stock, Class B common stock, stock conversion, corporate governance, Stockholders' Agreement, Bindley Capital, Pharmacy Investors, Cardinal Equity Fund, dual-class shares, IPO, corporate reorganization